Skip to main content
Mankind Pharma Limited logo

Mankind Pharma Limited — Investor Relations & Filings

Ticker · MANKIND ISIN · INE634S01028 LEI · 33580067G8AZ7S8NYA02 BSE.NS Manufacturing
Open in API
Filings indexed 397 across all filing types
Latest filing 2025-08-11 Regulatory Filings
Country IN India
Listing BSE.NS MANKIND

About Mankind Pharma Limited

https://www.mankindpharma.com/

Mankind Pharma Limited focuses on the development, manufacturing, and marketing of a broad spectrum of pharmaceutical formulations and consumer healthcare products. The company’s portfolio spans various therapeutic areas, including anti-infectives, cardiovascular, gastrointestinal, dermatology, and respiratory health. It maintains a significant presence in the over-the-counter segment with brands such as Manforce, Prega News, and Gas-O-Fast. The organization operates a robust research and development infrastructure dedicated to creating affordable and accessible medicinal solutions. Its operational model leverages an extensive distribution network to ensure product availability across diverse geographic regions, prioritizing high-quality healthcare delivery and patient-centric innovation.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges regarding the company's participation in upcoming investor conferences. It references compliance with SEBI Listing Obligations and Disclosure Requirements, 2015, and provides a schedule of investor events. There is no financial data, report, or detailed presentation included. The document is an announcement of participation in investor conferences, which is a regulatory disclosure but does not fit into categories like Investor Presentation (IP) because it does not contain detailed financial or strategic content. It is also not a report publication or certification. Therefore, the best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other categories.
2025-08-11 English
Change in Management
Board/Management Information Classification · 95% confidence The document is an official communication dated August 8, 2025, addressed to stock exchanges regarding the appointment of Secretarial Auditors approved at the 34th Annual General Meeting held on August 7, 2025. It references compliance with SEBI Listing Regulations and provides detailed disclosure about the appointment of auditors. The content focuses on informing regulatory bodies and shareholders about a board/management-related change rather than presenting financial data or audit results. The document length is 3914 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, it fits best under the category of Board/Management Information (MANG), as it announces a change in company auditors, a senior management-related appointment.
2025-08-08 English
Shareholders meeting
Regulatory Filings
2025-08-08 English
Shareholders meeting
AGM Information Classification · 95% confidence The document is titled 'Proceedings of the 34th Annual General Meeting (AGM) of Mankind Pharma Limited' and is dated August 7, 2025. It details the conduct of the AGM, including attendance, agenda items, voting procedures, and resolutions passed. It references the Annual Report and Auditor's Report as already circulated but does not contain the full financial statements or detailed financial data itself. The document is a summary of the AGM proceedings rather than the full Annual Report or financial statements. Therefore, it fits the category of AGM Information (AGM-R). The document length (10,239 characters) supports that it is a detailed summary of the meeting proceedings rather than a brief announcement or a full report.
2025-08-07 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 100% confidence The document is a detailed transcript of an investor conference call for the first quarter of fiscal year 2026 (Q1 FY26) for Mankind Pharma Limited. It includes management commentary on financial results, business performance, operational highlights, and a Q&A session with analysts. The text explicitly mentions it is a transcript of the earnings conference call held on August 1, 2025, and includes detailed financial figures, business updates, and forward-looking statements. This matches the definition of a Call Transcript (CT), which is a full text transcript of company conference calls such as earnings calls with Q&A. The document is not an earnings release (which would be a brief announcement), nor an annual or interim report, but a transcript of the call discussing quarterly results.
2025-08-06 English
General Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding the submission of an application for reclassification of certain shareholders from the Promoter & Promoter Group category to the Public category under SEBI Listing Regulations. It references regulatory compliance and shareholder category changes but does not contain financial statements, audit information, or detailed financial data. The document length is short (1608 characters) and is an announcement of a regulatory action rather than a report or detailed filing. This fits the category of a Regulatory Filing (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2025-08-03 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.